CONQUEST: The COllaboratioN on QUality improvement initiative for achieving Excellence in Standards of COPD care
Introducing CONQUEST
The COllaboratioN on QUality improvement initiative for achieving Excellence in STandards of Chronic Obstructive Pulmonary Disease (COPD) care (CONQUEST) is a novel, collaborative, interventional COPD registry. It comprises an integrated quality improvement programme focusing on patients (diagnosed and undiagnosed) at a modifiable and higher risk of COPD exacerbations. CONQUEST is underpinned by four evidence-based Quality Standards developed by 11 experts internationally recognised in their field.
CONQUEST drives long-term, targeted, patient-centred changes in COPD management. The promotion of expert and guideline-led care aims to reduce exacerbation frequency and improve healthcare outcomes.
About the CONQUEST Quality Improvement Programme
A programme supporting healthcare teams to identify opportunities for improved diagnosis, care and management of their COPD patients. The four quality standards have been translated into a programme of activities that embed quality improvement into routine care.
Get involved in CONQUEST
Healthcare systems wishing to join the CONQUEST programme should consider the elements key to QI implementation, spanning from site infrastructure through to data sharing.
If you are interested in implementing CONQUEST in your healthcare system or you wish to find out more about the programme and the resources available, please contact the team at:
info.conquest@optimumpatientcare.org
Building the CONQUEST Registry
Medical records from > 1,020,000 patients in the CONQUEST Registry
► 3 core locality areas involved
►168 primary sites recruited
►100% baseline data provided
► 3 integrated health care systems
►120 primary care teams recruited
► 100% baseline data provided
Evaluating CONQUEST: How will we know if the CONQUEST QI programme has improved care for COPD patients?
To formally evaluate the CONQUEST programme, two cluster randomised trials called PREVAIL will be run independently in primary care settings in the UK and US. PREVAIL stands for the ‘Pragmatic Evaluation of an Improvement Programme for People Living with Modifiable High-risk COPD’.
PREVAIL will assess patient health outcomes over an average of two years in each country, comparing primary care sites who received the CONQUEST intervention, to those who continued usual care for their COPD patients. This will tell us how well, and in what ways, the program improves care.
Should the CONQUEST program be found to be beneficial, it would offer a scalable approach to improving the long-term health of people with modifiable high-risk COPD.
Publications
Quality Standards
CONQUEST Quality Standards: For the Collaboration on Quality Improvement Initiative for Achieving Excellence in Standards of COPD Care
Int J Chron Obstruct Pulmon Dis
12 August 2021
Rachel Pullen, Marc Miravitlles, Anita Sharma, Dave Singh, Fernando Martinez, John R Hurst, Luis Alves, Mark Dransfield, Rongchang Chen, Shigeo Muro, Tonya Winders, Christopher Blango, Hana Muellerova, Frank Trudo, Paul Dorinsky, Marianna Alacqua, Tamsin Morris, Victoria Carter, Amy Couper, Rupert Jones, Konstantinos Kostikas, Ruth Murray, David B Price.
Global Operational Protocol
CONQUEST: A quality improvement program for defining and optimizing standards of care for modifiable high-risk COPD patients
Patient Relat Outcome Meas
23 February 2022
Luis Alves, Rachel Pullen, John R Hurst, Marc Miravitlles, Victoria Carter, Rongchang Chen, Amy Couper, Mark Dransfield, Alexander Evans, Antony Hardjojo, David Jones, Rupert Jones, Margee Kerr, Konstantinos Kostikas, Jonathan Marshall, Fernando Martinez, Marije van Melle, Ruth Murray, Shigeo Muro, Clementine Nordon, Michael Pollack, Chris Price, Anita Sharma, Dave Singh, Tonya Winders, David B Price.
UK Opportunity Analysis
Identification of key opportunities for optimising the management of high-risk COPD patients in the UK using the CONQUEST quality standards: an observational longitudinal study
Lancet Regional Health Europe
22 April 2023
David M. G. Halpin, Andrew P. Dickens, Derek Skinner, Ruth Murray, Mukesh Singh, Katherine Hickman, Victoria Carter, Amy Couper, Alexander Evans, Rachel Pullen, Shruti Menon, Tamsin Morris, Hana Muellerova, Mona Bafadhel, James Chalmers, Graham Devereux, Martin Gibson, John R. Hurst, Rupert Jones, Konstantinos Kostikas, Jennifer Quint, Dave Singh, Marije van Melle, Tom Wilkinson, David Price.
US Opportunity Analysis
Patterns of Care in the management of high-risk COPD in the US (2011-2019): an observational study for the CONQUEST quality improvement program
Lancet Regional Health Americas
28 July 2023
Margee Kerr, Yasir Tarabichi, Alexander Evans, Douglas Mapel, Wilson Pace, Victoria Carter, Amy Couper, M Bradley Drummond, Norbert Feigler, Alex Federman, Hitesh Gandhi, Nicola A Hanania, Alan Kaplan, Konstantinos Kostikas, Maja Kruszyk, Marije van Melle, Hana Müllerová, Ruth Murray, Jill Ohar, Michael Pollack, Rachel Pullen, Dennis Williams, Juan Wisnivesky, MeiLan K Han, Catherine Meldrum, David Price.
Australia Opportunity Analysis
Patterns of Care in the Management of High-Risk COPD in Australia (2015-2019): An Observational Study for the CONQUEST Quality Improvement Program
Lancet Regional Health Western Pacific
7 May 2025
Christine Jenkins, Andrew P Dickens, Alexander Evans, Porsche Le Cheng, Florian Heraud, Kerry Hancock, Anita Sharma, Belinda Cochrane, Alexander Roussos, Chantal Le Lievre, John Blakey, Sinthia Bosnic-Anticevich, Victoria Carter, Angelina Catanzariti, Clare Ghisla, Mark Hew, Brian Ko, Thao Le, Paul Leong, Vanessa M McDonald, Chi Ming Lau, Jennifer L Perret, Rachel Pullen, Kanchanamala Ranasinghe, Joan B Soriano, Deb Stewart, Marije van Melle, Russell Wiseman, and David Price.
High-risk COPD patient management opportunities: Australia, US and UK comparisons
Opportunities to optimise the management of high-risk COPD: Comparing Australian observational data from 2019 with analogous data from the US and UK
Presented at TSANZSRS 2025
23 March 2025
Belinda Cochrane, Amy Couper, Rachel Pullen, Andrew P Dickens, Alexander Evans, Porsche Le Cheng, Jennifer Perret, Sinthia Bosnic-Anticevich, Margee Kerr, Fabio Botini, Victoria Carter, Angelina Catanzariti, Kerry Hancock, Mark Hew, Christine Jenkins, Brian Ko, Thao Le, Paul Leong, Chantal Le Lievre, Vanessa McDonald, Ruth Murray, Alexander Roussos, Peter Smith, Deb Stewart, Kanchanamala Ranasinghe and David Price.
CONQUEST Collaborators
Global Committee Members
Committee Type | Committee Member | Committee Affiliation | Country Represented |
|---|---|---|---|
Global | Anita Sharma | Platinum Medical Center, Queensland | Australia |
Global | Daiana Stolz | University of Freiberg, Freiberg | Germany |
Global | Dave Singh | The University of Manchester, Manchester | United Kingdom |
Global | David Price | Observational and Pragmatic Research Institute, Singapore | Singapore |
Global | Fernando Martinez | Weill Cornell Medicine, New York | United States of America |
Global | John Hurst | University College London, London |
United Kingdom |
Global | Luis Alves | University of Porto, Porto | Portugal |
Global | Marc Miravitlles | Vall d’Hebron University Hospital, Barcelona | Spain |
Global | Mohit Bhutani | University Of Alberta, Alberta | Canada |
Global | Rongchang Chen | Shenzhen Institute of Respiratory Diseases, and the Guangzhou Institute of Respiratory Health, Guangzhou | China |
Global | Shigeo Muro | Nara Medical University, Nara | Japan |
Global | Tonya Winders | The Global Allergy & Airways Patient Platform | United States of America |
United Kingdom Committee Members
Committee Type | Committee Member | Committee Affiliation | Country Represented |
|---|---|---|---|
National (UK)
| Chris Gale | University of Leeds, Leeds, England | United Kingdom |
National (UK) | David Halpin |
University of Exeter, Exeter, England | United Kingdom |
National (UK)
| Elango Vijaykumar | Executive Partner at East Surrey Modality Partnership; National Research Lead Modality Partnership | United Kingdom |
National (UK)
| Graham Devereux
| Liverpool School of Tropical Medicine, Liverpool, England | United Kingdom |
National (UK)
| James Chalmers | University of Dundee, Dundee, Scotland | United Kingdom |
National (UK) | Jennifer Quint | Imperial College London, London, England | United Kingdom |
National (UK) | Katherine Hickman | Low Moor Medical Practice, Bradford, and National Health Service (NHS) West Yorkshire Integrated Care Board, England | United Kingdom |
National (UK) | Martin Gibson | The University of Manchester, and North West E-Health, Manchester, England | United Kingdom |
National (UK) | Michael Crooks | The University of Hull, and Hull University Teaching Hospitals NHS Trust, Hull, England | United Kingdom |
National (UK) | Mona Bafadhel | King’s College London, London, England | United Kingdom |
National (UK) | Mukesh Singh |
Horse Fair Practice Group, Rugeley, and Keele University Medical School, Staffordshire, England | United Kingdom |
National (UK) | Tom Wilkinson | University of Southampton, Southampton, England | United Kingdom |
United States Committee Members
Committee Type | Committee Member | Committee Member Affiliation | Country Represented |
|---|---|---|---|
National (USA) | Alan Kaplan | The University of Toronto, Toronto, and the Family Physician Airways Group of Canada, Ontario | Canada |
National (USA) | Barry Make | National Jewish Health, Denver, Colorado | United States of America |
National (USA) | M. Bradley Drummond | University of North Carolina at Chapel Hill, North Carolina | United States of America |
National (USA) | Catherine Meldrum | University of Michigan, Ann Arbor, Michigan | United States of America |
National (USA) | Douglas Mapel | Northern Arizona Pulmonary Associates, Arizona | United States of America |
National (USA) | Jill Ohar | Wake Forest University, Winston-Salem, North Carolina | United States of America |
National (USA) | MeiLan Han | University of Michigan, Ann Arbor, Michigan | United States of America |
National (USA) | Nick Hanania | Baylor College of Medicine, Houston, Texas | United States of America |
National (USA) | Tonya Winders | The Global Allergy & Airways Patient Platform | United States of America |
National (USA) | Wilson Pace | DARTNet Institute, Aurora, and the University of Colorado, Denver, Colorado | United States of America |
NETWORK
CONQUEST Network and Database
.png)
A European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP®) Registered Datasource (ENCEPP/DSPP/42512)
CONTACT
For further information on the CONQUEST quality improvement programme please contact the team at:
5 Coles Lane, Oakington, Cambridgeshire, CB24 3BA, UK
CONQUEST is co-funded by Optimum Patient Care Global Limited and AstraZeneca Ltd. AstraZeneca is the sole external funder of this work.
Optimum Patient Care’s Facilities and Administration Costs Policies (for US institutions/projects only) It is the policy of Optimum Patient Care Limited (OPC) to charge facilities and administration fees (F&A) for grants and contracts undertaken by OPC. In cases other than where a set federal F&A rate has been established, OPC will accept the specific F&A rate publicly established by a given not-for-profit funding agency for grant or contract activities as long as it meets or exceeds the currently established OPC minimum rate. The minimum acceptable F&A rate of OPC is 10% without special dispensation. The F&A rate for industry funded grants and contracts is 25% and it is OPC policy to not pay a higher rate than this. OPC will distribute F&A fees to sub-contractors prorated to the direct costs included in the sub-contract. OPC will pay sub-contractors the facilities and administration percentage of direct costs as established by the specific funding agency for a particular grant, or for federal grants at the established federal rate for the sub-contractor. OPC will also collect facility and administration fees on the first $25,000 of a sub-contract for the life of a grant or contract. The sub-contractor may also request facilities and administration fees for the initial $25,000 of a sub-contract. If duplicate facilities and administration fees are not allowed for sub-contracts by a funding agency then the fees associated with the first $25,000 of direct costs will be equally paid to the sub-contractor and OPC. OPC does not pay facilities and administration fees for purchased services or consultation services.